Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

Journal of Clinical Oncology

Volumn 28, Issue 12, 2010, Pages 2077-2084

  Ladetto, Marco ^a   Pagliano, Gloria ^a   Ferrero, Simone ^a   Cavallo, Federica ^a   Drandi, Daniela ^a   Santo, Loredana ^a   Crippa, Claudia ^a   De Rosa, Luca ^a   Pregno, Patrizia ^a   Grasso, Mariella ^a   Liberati, Anna Marina ^a   Caravita, Tommaso ^a   Pisani, Francesco ^a   Guglielmelli, Tommasina ^a   Callea, Vincenzo ^a   Musto, Pellegrino ^a   Cangialosi, Clotilde ^a   Passera, Roberto ^a   Boccadoro, Mario ^a   Palumbo, Antonio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN HEAVY CHAIN; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ALLOTRANSPLANTATION; ANEMIA; ARTICLE; AUTOGRAFT; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRONCHITIS; CANCER REGRESSION; CLINICAL ARTICLE; CONSTIPATION; DIZZINESS; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOTENSION; MALE; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MYELOMA; NEUROPATHIC PAIN; NEUTROPENIA; PARESTHESIA; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYREXIA IDIOPATHICA; RASH; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; AUTOTRANSPLANTATION; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETICS; IMMUNOGLOBULIN HEAVY CHAIN GENE; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE MYELOMA; PATHOLOGY; POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 77951625298     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.7172     Document Type: Article

References (47)

1. Vesole DH, Zhang L, Flomenberg N, et al: A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: An analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant 15:83-91, 2009
2. Bruno B, Rotta M, Patriarca F, et al: Nonmyeloablative allografting for newly diagnosed multiple myeloma: The experience of the Gruppo Italiano Trapianti di Midollo. Blood 113:3375-3382, 2009
3. Rotta M, Storer BE, Sahebi F, et al: Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 113:3383-3391, 2009
4. Bruno B, Rotta M, Patriarca F, et al: A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356:1110-1120, 2007 (Pubitemid 46425595)
5. Levenga H, Levison-Keating S, Schattenberg AV, et al: Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplant 40:355-359, 2007 (Pubitemid 47202420)
6. Corradini P, Tarella C, Olivieri A, et al: Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remission in patients with poor-risk hematologic malignancies. Blood 99:75-82, 2002
7. Martinelli G, Terragna C, Zamagni E, et al: Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 18:2273-2281, 2000 (Pubitemid 30350220)
8. Cavo M, Terragna C, Martinelli G, et al: Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 96:355-357, 2000 (Pubitemid 30456493)
9. Corradini P, Voena C, Tarella C, et al: Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 17:208-215, 1999 (Pubitemid 29022395)
10. Corradini P, Voena C, Astolfi M, et al: High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85:1596-1602, 1995
11. Bakkus MH, Bouko Y, Samson D, et al: Posttransplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol 126:665-674, 2004 (Pubitemid 39221301)
12. Fenk R, Ak M, Kobbe G, et al: Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica 89:557-566, 2004 (Pubitemid 38691243)
13. Corradini P, Cavo M, Lokhorst H, et al: Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in multiple myeloma. Blood 102:1927-1929, 2003
14. Voena C, Malnati M, Majolino I, et al: Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. Bone Marrow Transplant 32:791-793, 2003 (Pubitemid 38455943)
15. Lipinski E, Cremer FW, Ho AD, et al: Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 28:957-962, 2001 (Pubitemid 33130239)
16. Davies FE, Forsyth PD, Rawstron AC, et al: The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 112:814-819, 2001 (Pubitemid 32222857)
17. Ocio EM, Mateos MV, Maiso P, et al: New drugs in multiple myeloma: Mechanisms of action and phase I/II clinical findings. Lancet Oncol 9:1157-1165, 2008
18. Palumbo A, Facon T, Sonneveld P, et al: Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111:3968-3977, 2008
19. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008
20. Podar K, Chauhan D, Anderson KC: Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23:10-24, 2009
21. Li WW, Hutnik M, Gehr G: Antiangiogenesis in haematological malignancies. Br J Haematol 143:622-631, 2008
22. Hideshima T, Anderson KC: Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am 21:1071-1091, 2007 (Pubitemid 350051352)
23. Mitsiades CS, Mitsiades NS, Munshi NC, et al: The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 42:1564-1573, 2006 (Pubitemid 44118771)
24. Chauhan D, Hideshima T, Mitsiades C, et al: Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4:686-692, 2005 (Pubitemid 40601851)
25. Anderson KC: Moving disease biology from the lab to the clinic. Cancer 97:796-801, 2003
26. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001 (Pubitemid 32691956)
27. Pineda-Roman M, Zangari M, van Rhee F, et al: VTD combination therapy with bortezomibthalidomide- dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22:1419-1427, 2008 (Pubitemid 352006086)
28. Palumbo A, Ambrosini MT, Benevolo G, et al: Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109: 2767-2772, 2007 (Pubitemid 46482069)
29. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005 (Pubitemid 41007864)
30. Chauhan D, Li G, Auclair D, et al: 2-Methoxyestardiol and bortezomib/proteasomeinhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis 9:149-155, 2004 (Pubitemid 38987592)
31. Mitsiades N, Mitsiades CS, Richardson PG, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 101:2377-2380, 2003 (Pubitemid 36302084)
32. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000
33. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006 (Pubitemid 44264086)
34. Voena C, Ladetto M, Astolfi M, et al: A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 11:1793-1798, 1997 (Pubitemid 27458621)
35. Ladetto M, Donovan JW, Harig S, et al: Realtime polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 6:241-253, 2000
36. Donovan JW, Ladetto M, Zou G, et al: Immunoglobulin heavy-chain consensus probes for realtime PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 95:2651-2658, 2000 (Pubitemid 30210546)
37. Ladetto M, Mantoan B, De Marco F, et al: Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as longterm persisting clonal populations. Exp Hematol 34:1680-1686, 2006 (Pubitemid 44839012)
38. van der Velden VH, Cazzaniga G, Schrauder A, et al: Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 21: 604-611, 2007 (Pubitemid 46444541)
39. Singhal S, Powles R, Milan S, et al: Kinetics of paraprotein clearance after autografting for multiple myeloma. Bone Marrow Transplant 16:537-540, 1995
40. Zangari M, van Rhee F, Anaissie E, et al: Eight-year median survival in multiple myeloma after total therapy 2: Roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol 141:433-444, 2008 (Pubitemid 351550542)
41. Abdelkefi A, Ladeb S, Torjman L, et al: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial. Blood 111:1805-1810, 2008
42. Palumbo A, Falco P, Gay F, et al: Bortezomib-doxorubicin-dexamethasone as induction prior to reduced autologous transplantation followed by lenalidomide as consolidation/maintenance in elderly untreated myeloma patients. Blood 112:11, 2008 (abstr 159)
43. Cook G, Bird JM, Marks DI: In pursuit of the allo-immune response in multiple myeloma: Where do we go from here? Bone Marrow Transplant 43:91-99, 2009
44. Barlogie B, Tricot G, Anaissie E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030, 2006 (Pubitemid 43357806)
45. González D, González M, Alonso ME, et al: Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. Leukemia 17:1051-1057, 2003 (Pubitemid 36722235)
46. Paiva B, Vidriales MB, Cerveró J, et al: Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017-4023, 2008
47. Sarasquete ME, García-Sanz R, González D, et al: Minimal residual disease monitoring in multiple myeloma: A comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 90:1365-1372, 2005 (Pubitemid 41503652)